Positive Mo-Rez Phase Ib data in ovarian cancer

GSK reports strong phase I Mo-Rez results but faces high toxicity and long timelines.

What the company is saying

GSK plc is highlighting positive phase I BEHOLD-1 trial results for mocertatug rezetecan (Mo-Rez) in platinum-resistant ovarian cancer, emphasizing a 62% confirmed objective response rate and a median duration of response of 12.2 months at the selected phase III dose. The company frames these results as clinically meaningful and durable, with Senior Vice President Hesham Abdullah stating that responses and durability are maintained over time in a difficult-to-treat setting. GSK stresses that five pivotal phase III studies are now underway across gynaecological cancers, presenting this as evidence of accelerated development. The announcement underscores the manageable safety profile but acknowledges that 71% of patients experienced grade ≥3 treatment-related adverse events, predominantly haematologic, with 2% discontinuing due to toxicity. Investigator Vanda Salutari adds that the observed duration of response and progression-free survival are encouraging relative to typical outcomes in this patient population. The company’s tone is confident, focusing on the broad potential of Mo-Rez and the scale of its ongoing late-stage programme.

What the data suggests

The BEHOLD-1 phase Ib trial for Mo-Rez in platinum-resistant ovarian cancer achieved a confirmed objective response rate of 62% (28 of 45 patients; 95% CI: 46.5–76.2%) at the 5.8 mg/kg dose, with a median duration of response of 12.2 months (95% CI: 7.0–12.7) and median progression-free survival of 11.1 months (95% CI: 8.3–13.9). These efficacy figures are notable in a setting where treatment options are limited and outcomes are poor. However, safety data show that 71% of patients experienced grade ≥3 treatment-related adverse events, mostly haematologic, with 51% requiring dose interruptions and 47% needing dose reductions. Treatment discontinuation and interstitial lung disease/pneumonitis each occurred in 2% of patients. The trial enrolled 136 platinum-resistant ovarian cancer patients in total. No financial data, commercial projections, or cost disclosures are provided. The data support continued phase III development, but the high rate of severe adverse events signals a challenging risk-benefit profile.

Analysis

The announcement presents robust phase I clinical data for Mo-Rez in platinum-resistant ovarian cancer, with clear efficacy and safety metrics (cORR 62%, median DoR 12.2 months, median PFS 11.1 months). These realised results are well-supported by numerical evidence. However, the tone is notably positive and forward-looking, emphasizing the acceleration and scale of the phase III programme (five pivotal trials underway), which is capital intensive and will not yield commercial or patient benefit in the near term. No financial metrics (revenue, profit, R&D spend) are disclosed, and there is no evidence of immediate earnings impact. The majority of forward-looking claims relate to ongoing or future studies, not realised milestones. The gap between narrative and evidence lies in the framing of the phase III programme as a near-term value driver, when in reality, benefits are long-term and subject to clinical and regulatory risk.

Risk flags

• ●The high incidence of grade ≥3 treatment-related adverse events (71%) raises concerns about tolerability and real-world adoption, as severe toxicity can limit use even if efficacy is strong.
• ●Execution risk is significant, with five large-scale phase III trials underway but no phase III efficacy or safety data disclosed; failure in any of these trials could halt development.
• ●The absence of financial, cost, or commercialisation data leaves investors unable to assess the economic viability or potential return on investment for Mo-Rez.
• ●Regulatory risk remains high, as phase I results do not guarantee phase III success or approval, especially given the challenging safety profile.
• ●The development timeline is long, with no near-term catalysts; investors face a multi-year wait for pivotal data and any potential revenue.

Bottom line

GSK’s phase I data for Mo-Rez in platinum-resistant ovarian cancer show a 62% response rate and median progression-free survival of 11.1 months, which are strong signals in a hard-to-treat population. However, the high rate of severe adverse events (71% grade ≥3) and frequent dose modifications highlight substantial safety concerns. The company is committing significant resources to five phase III trials, but no phase III results or regulatory milestones are available, making this a long-term, high-risk proposition. No financial or commercial data are disclosed, so the investment case rests entirely on future clinical and regulatory outcomes. The most important takeaway is that while early efficacy is promising, the risk-benefit profile and long path to market mean investors should expect volatility and uncertainty until pivotal data emerge.

Announcement summary

(LSE:GSK) GSK plc announced updated results from the global phase I BEHOLD-1 trial for mocertatug rezetecan (Mo-Rez), an investigational B7-H4-targeted antibody-drug conjugate, in platinum-resistant ovarian cancer (PROC). The data, presented at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, showed a confirmed objective response rate (cORR) of 62% (n=28/45; 95% CI: 46.5-76.2%) at the selected phase III dose of 5.8 mg/kg. The median duration of response (DoR) was 12.2 months (95% CI: 7.0-12.7), and the median progression-free survival (PFS) was 11.1 months (95% CI: 8.3-13.9). Grade ≥3 treatment-related adverse events (TRAEs) were observed in 71% (n=32/45) of patients, predominantly haematologic. TRAEs led to treatment discontinuation in 2% (n=1/45) and interstitial lung disease (ILD)/pneumonitis occurred in 2% (n=1/45) of patients. Dose interruptions due to TRAEs occurred in 51% of PROC patients, and dose reductions in 47%. At data cut-off, 136 PROC patients were enrolled in BEHOLD-1. Five pivotal phase III trials are underway across gynaecological cancers: BEHOLD-Ovarian01 (platinum-resistant ovarian cancer), BEHOLD-Ovarian02 (platinum-sensitive ovarian cancer), BEHOLD-Ovarian03 (first-line maintenance for ovarian cancer without homologous recombination deficiency), BEHOLD-Endometrial01 (second-line advanced/recurrent endometrial cancer), and BEHOLD-Endometrial02 (first-line maintenance for mismatch repair proficient endometrial cancer). The BEHOLD-1 trial is a two-part, open-label, phase I study evaluating safety, tolerability, and efficacy of Mo-Rez in PROC or advanced/recurrent endometrial cancer (EC). The selected phase III dose is being evaluated in ongoing studies. Mo-Rez is composed of a fully human anti-B7-H4 monoclonal antibody covalently linked to a topoisomerase inhibitor payload, with a drug-to-antibody ratio (DAR) of 6. GSK holds exclusive worldwide rights to Mo-Rez, excluding mainland China, Hong Kong, Macau, and Taiwan, under license from Hansoh Pharma. Ovarian cancer affects 843,000 people globally, with 240,000 new cases annually. 70% of people with ovarian cancer present with advanced disease. The BEHOLD-1 results support the continued phase III development of Mo-Rez in ovarian and endometrial cancers.

Disagree with this article?